| Prev Close | 92.57 |
| Day Low/High | 92.20 / 93.00 |
| 52 Wk Low/High | 62.55 / 101.28 |
AbbVie, Inc. (ABBV)
92.92
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1764.83B |
| Market Cap | 163.37B |
| P/E Ratio | 80.39 |
| Div & Yield | N.A. (N.A) |
Have a CIGAR, You'll Go Far in 2016
5 biotech stocks that could outperform the overall market in 2016.
Avoid These Investment Mistakes in 2016
Don't catch falling knives, and don't ignore dividends.
3 Biotech Stocks to Buy into 2016
GILD, CELG and ABBV will lead the biotech resurgence.
AstraZeneca to Pay $4 Billion for 55 Percent of Acerta Pharma
United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.
Cramer: Dow Chemical-DuPont Merger Will Instantly Create Value
The merged company can become multiple companies.
6 Dowdy Drug Stocks to Consider for 2016
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Stocks to Watch for 2016 M&A Deals
Look for 2015's record run of mergers and acquisitions to continue.
Don't Abandon the Biotech Ship
There's too much good out there.
Apple and 3 Other Dirt-Cheap Stocks That Investors Could Buy in 2016
Here is where to find value next year.
Apple and Other Dirt-Cheap Stocks
Here is where to find value next year.
Gilead Leads a Biotech Rally
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Gilead Leads a Biotech Rally
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
2 Safe and Cheap Health Care Stocks
These two will continue to churn out earnings growth.
AbbVie and Michael Kors Rally Amid a Mixed Market
The market has strengthened some since my last update. Apple (AAPL) definitely seems to acting better since its earnings report, and is back above some important moving-day averages. Jim Cramer is right about the stock -- it's one you should hold, n...
3 Health Care Names With Healthy Outlooks
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
Hewlett Packard Split Gets Analysts' Attention; Abbvie Gets Upgraded
In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost.
Closing Bell: AbbVie Climbs on Sales Jump; Stocks Up in October
Stocks ended slightly lower Friday, but enjoyed their best monthly gain in four years in October.
It's One Yawner of a Trading Day
Markets are now up slightly in what is one of most listless trading sessions to end a month that I recall lately. Not much moving. As previously noted, AbbVie (ABBV) might be the standout in the S&P 500 today. It's up more than 10% in trading today...
3 Stocks to Watch Today
Futures are up as we get less than an hour from the opening bell for October's last trading day. Earnings reports continued to hit fast and furious this morning, as about one third of S&P 500 companies report quarterly numbers this week. Here are th...
What to Watch Friday: AB InBev Hands Us Its Latest Earnings on Tap
For Friday October 30, TheStreet awaits quarterly results from Exxon Mobil (XOM), Chevron (CVX), Phillips 66 (PSX), Anheuser-Busch InBev (BUD), CVS Health (CVS) and AbbVie (ABBV).
Here's What I See in Apple and Amazon
The Apple breakout over $117 now measures to $127.
Gilead Wins in Hepatitis C Market
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
Gilead Wins in Hepatitis C Market
ABBV gets FDA warning on Viekira Pak drug, GILD reaps the reward.
Biowreck (Part Deux)
The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.
Biotechs, Autos Look Good in This Selloff
Put cash to work in large-caps that have become cheap in the current market.
Why I'm Adding to My Biotech Positions
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
My Take on Stock Buybacks
One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...
AbbVie Looks Like It's Bottoming Out
Charts show the drug firm has a good entry point approaching.
